Long term risk and costs of bleeding in men and women treated with triple antithrombotic therapy-An observational study.
Anna HolmMartin HenrikssonJoakim AlfredssonMagnus JanzonTherese JohanssonEva SwahnDominique VialSofia Sederholm LawessonPublished in: PloS one (2021)
The high bleeding incidence in patients with TAT, especially in women, is a cause of concern. There is a need for an adequately sized randomised, controlled trial to determine a safe but still effective treatment for these patients.
Keyphrases
- atrial fibrillation
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- study protocol
- risk factors
- prognostic factors
- stem cells
- randomized controlled trial
- type diabetes
- clinical trial
- patient reported outcomes
- breast cancer risk
- replacement therapy
- patient reported
- pregnancy outcomes